About Kleo Pharmaceuticals
Kleo Pharmaceuticals is a company based in New Haven (United States) founded in 2015 was acquired by Biohaven Pharmaceutical in January 2021. Kleo Pharmaceuticals has raised $34.74 million across 4 funding rounds from investors including Biohaven Pharmaceutical, Gates Foundation and PeptiDream. The company has 20 employees as of December 31, 2022. Kleo Pharmaceuticals operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter New Haven, United States
- Employees 20 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Kleo Pharmaceuticals Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.74 M (USD)
in 4 rounds
-
Latest Funding Round
$5 M (USD), Grant
Jul 08, 2020
-
Investors
Biohaven Pharmaceutical
& 2 more
-
Employee Count
20
as on Dec 31, 2022
-
Acquired by
Biohaven Pharmaceutical
(Jan 08, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Kleo Pharmaceuticals
Kleo Pharmaceuticals has successfully raised a total of $34.74M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $5 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kleo Pharmaceuticals
Kleo Pharmaceuticals has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Biohaven Pharmaceutical, Gates Foundation and PeptiDream.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapies for neurological and neuropsychiatric diseases are developed.
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked | |
|
Peptide-based drugs are developed for diverse medical indications.
|
Locked | Locked | Locked |
Investor details for Kleo Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kleo Pharmaceuticals
Investment portfolio details for Kleo Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kleo Pharmaceuticals
Detailed financials for Kleo Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kleo Pharmaceuticals Comparisons
Peer comparison for Kleo Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kleo Pharmaceuticals
Kleo Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Kleo Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kleo Pharmaceuticals
Complete news archive for Kleo Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kleo Pharmaceuticals
Kleo Pharmaceuticals was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Kleo Pharmaceuticals is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Kleo Pharmaceuticals is a funded company, having raised a total of $34.74M across 4 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Kleo Pharmaceuticals is 20.
Kleo Pharmaceuticals is developing a new class of immunotherapies utilizing small molecules to activate an individuals own immune system to fight against cancers and infectious diseases. It is developing two types of small molecules Antibody-Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). ARMs are bifunctional or two-headed chemical structures designed such that one head interacts with disease-relevant molecular targets (such as cancers), while the other head interacts directly with antibodies already present in a persons bloodstream. SyAMs are novel synthetic molecules that possess both the targeting and effector cell-activating functions of antibodies.
Kleo Pharmaceuticals's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Kleo Pharmaceuticals has 3 investors. Key investors include Biohaven Pharmaceutical, Gates Foundation, and PeptiDream.